Stryker (SYK) Stock Forecast & Price Target

Stryker's notable growth is highlighted by a 7.6% increase in knee replacements in the U.S. and 8.8% internationally, attributed to the success of robotic-assisted procedures and new Mako installations, which have significantly boosted sales. The company's operating margin improved to 30.2%, exceeding expectations and reflecting efficient management and strong demand. Additionally, Stryker experienced broad-based organic growth of 11.0% in 4Q25, driven by increased procedure volumes and a robust pipeline of new products, indicating a solid competitive position in the medical equipment market.

Stryker faces a negative outlook primarily due to disruptions from recent acquisitions and a deceleration in the utilization of its Mako robotic systems as competitive alternatives emerge, which could significantly hinder revenue growth. The bear case scenario suggests organic revenue growth may slow to 8% or less, compounded by margin pressures, unsuccessful product launches, and potential earnings dilution resulting from acquisitions, ultimately leading to below-consensus earnings expectations. Additionally, Stryker's gross margin decreased by 10 basis points year-over-year, with operating margins experiencing only marginal improvement, while an ongoing slowdown in the orthopedic market and capital spending in hospitals poses further risks to financial performance.